AGRX Agile Therapeutics Inc.

2.82
-0.11  -4%
Previous Close 2.93
Open 2.93
Price To Book 5.22
Market Cap 196,836,000
Shares 69,800,000
Volume 1,749,067
Short Ratio
Av. Daily Volume 5,269,972
Stock charts supplied by TradingView

NewsSee all news

  1. Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

    PRINCETON, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare

  2. Agile Therapeutics Strengthens Commercial Leadership Team

    PRINCETON, N.J., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced the appointment of Kimberly Whelan as Vice President of Market Access. Ms. Whelan

  3. Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco

    PRINCETON, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be

  4. Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

    PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription

  5. Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)

    Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced a positive outcome

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRLs issued 2013 and 2017. New PDUFA extended by three months to February 16, 2020. Advisory Committee Meeting October 30, 2019 voted 14 to 1 in favor.
Twirla
Contraceptive patch

Latest News

  1. Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

    PRINCETON, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare

  2. Agile Therapeutics Strengthens Commercial Leadership Team

    PRINCETON, N.J., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced the appointment of Kimberly Whelan as Vice President of Market Access. Ms. Whelan

  3. Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco

    PRINCETON, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be

  4. Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

    PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription

  5. Agile Therapeutics Announces Favorable Outcome of FDA Advisory Committee Meeting for its Investigational Transdermal Contraceptive Patch, Twirla® (AG200-15)

    Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced a positive outcome

  6. Agile Therapeutics to Present at Upcoming Investor Conferences

    PRINCETON, N.J., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at